Abnova UK and European Distributor - Antibodies, Recombinant Proteins and Assay Kits for Life Science Research

Abnova, Antibodies and Recombinant Proteins

Abnova is the world's largest monoclonal antibody manufacturer with a capacity for generating 300 mouse monoclonal antibodies and 200 rabbit polyclonal antibodies per month.

Abnova takes a genomic/proteomic approach towards antibody development, their goal being to have at least one antibody to every gene expressed in the human genome. In most cases, multiple clones are available for monoclonal antibodies. All recombinant proteins and antibodies are produced 'in house' in a state-of-the-art facility in Taiwan.

Abnova offers a unique complete monoclonal antibody and protein experience for customers that is different to traditional custom production companies and laboratories. They have an Industrial-Scale Infrastructure; maintaining a streamlined monoclonal production facility with scalable capacity for up to 500 immunizations per month, and a state-of-the-art specific pathogen free (SPF) facility, which has the breeding and holding capacity for 10,000+ mice. They also have a Wheat Germ In Vitro Protein Expression System. This is a high throughput protein production facility allowing soluble expression of conformationally correct protein, either from full-length cDNA or specific domains.

Abnova Production Technologies

Caltag Medsystems are a UK distributor of Abnova products, bringing UK based customer service and technical support to scientists within the UK and Ireland.

Blog posts

nanoCAR-T mRNA Service

Non-viral chimeric antigen receptor (CAR)-T cells are gaining attention for their cancer-killing ability with reduced side effects. Traditional CAR-T…

More

FISH & mutaFISH™ Probes

Abnova has developed a range of FISH probes and validated mutaFISH™ (mutation-specific Fluorescence In Situ Hybridisation) probes.

More

VHH Antibody Applications

VHH Abs, derived from heavy-chain-only IgG Abs in the Camelidae family, present unique & exceptional potential in diverse fields of research/medicine.

More

miRNA In Situ Hybridisation

miRNA in situ hybridisation is a powerful technique that allows researchers to visualise and localise miRNAs within cells and tissues.

More

Documents

  Category Title  
VHH nanoBiTE™ ServiceService DocumentsVHH nanoBiTE™ Service  View
Abnovas VHH nanoBiTE™ service focuses on developing bispecific VHH antibodies without an Fc domain, ideal for immune and tumor cell redirecting, multiple epitope targeting, and novel immuno-oncology research. Their smaller molecular size enhances tissue penetration, making them suitable for hard-to-access areas like the tumor microenvironment. The absence of an Fc region prevents unwanted immune activation by avoiding Fc receptor binding, supporting precise mechanistic action. Engineered through the genetic fusion of two VHH domains via a flexible peptide linker, VHH nanoBiTE™ ensures robust antigen binding with reduced production complexity.  
Neuroscience BioreagentsNeuroscience DocumentsNeuroscience Bioreagents  View
Advanced Solutions to Enhance Neuroscience Research  
CellTx Cell TherapyCell & Gene Therapy DocumentsCellTx Cell Therapy  View
Impactful Bioreagents and Media to Accelerate Cell Therapy Research and Manufacturing  
NanoAb ServiceService DocumentsNanoAb Service  View
Abnova offers the NanoAb™ service for the production of target-specific VHH antibodies from the camelid VHH library.  
Breast Cancer AntibodiesCancer DocumentsBreast Cancer Antibodies  View
Abnova provides a range of antibodies for Breast Cancer.  
Bladder Cancer AntibodiesCancer DocumentsBladder Cancer Antibodies  View
Abnova provides a range of antibodies for bladder cancer.  
New Bioactive ProteinsProteins DocumentsNew Bioactive Proteins  View
Abnovas new bioactive proteins offer exceptional purity and confirmed bioactivity, making them indispensable for various research applications. These proteins, which include CD Proteins, MHC Proteins, Immune Checkpoint Proteins, FGFR Family Proteins, VLP-Displayed Antigens, and other targets, are produced using HEK293 mammalian expression systems to maintain their natural conformation and functionality. All bioactive proteins undergo functional assays to confirm their activity. Through rigorous HPLC analysis, all products achieve over 95% purity. Additionally, the endotoxin levels are less than 1EU/μg detected by the LAL method, ensuring that Abnovas bioactive proteins meet the highest standards for research and therapeutic development.  
Tumour-Associated Antigens of CAR T Cell TherapyCancer DocumentsTumour-Associated Antigens of CAR T Cell Therapy  View
Abnova provides a range of Tumour-Associated Antigens of CAR T Cell Therapy.  
Innate Immunity: TNF-TRAF SignallingImmunology DocumentsInnate Immunity: TNF-TRAF Signalling  View
Abnova provides a range of antibodies for research into TNF-TRAF Signalling.  
The Role of Tumour Necrosis Factor in Amyotrophic Lateral SclerosisNeuroscience DocumentsThe Role of Tumour Necrosis Factor in Amyotrophic Lateral Sclerosis  View
Abnova provides a range of reagents for research into the role of Tumour Necrosis Factor in Amyotrophic Lateral Sclerosis.  
Show more...